ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) continues to be among the most common
diseases seen by gastroenterologists, surgeons, and primary care physicians. Our …
diseases seen by gastroenterologists, surgeons, and primary care physicians. Our …
Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group
Description: This update of the 2010 International Consensus Recommendations on the
Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines …
Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding (UGIB) refines …
[HTML][HTML] Antiplatelet therapy for atherothrombotic disease in 2022—from population to patient-centered approaches
G Jourdi, A Godier, M Lordkipanidzé… - Frontiers in …, 2022 - frontiersin.org
Antiplatelet agents, with aspirin (ASA) and P2Y12 receptor antagonists as major key
molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic …
molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic …
[HTML][HTML] Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis
H Guo, Z Ye, R Huang - Frontiers in Pharmacology, 2021 - frontiersin.org
Background: The safety and efficacy associated with the use of proton pump inhibitors (PPIs)
by patients with coronary artery disease receiving dual antiplatelet therapy (DAPT) remain …
by patients with coronary artery disease receiving dual antiplatelet therapy (DAPT) remain …
[HTML][HTML] Co-prescription of dual-antiplatelet therapy and proton pump inhibitors: current guidelines
H Saven, L Zhong, IM McFarlane - Cureus, 2022 - ncbi.nlm.nih.gov
Dual-antiplatelet therapy (DAPT) prevents thrombotic complications associated with
coronary artery disease, acute coronary syndrome, and stent thrombosis following the …
coronary artery disease, acute coronary syndrome, and stent thrombosis following the …
Does the long-term administration of proton pump inhibitors increase the risk of adverse cardiovascular outcomes? A ChatGPT powered umbrella review
E Teperikidis, A Boulmpou, V Potoupni, S Kundu… - Acta …, 2023 - Taylor & Francis
Abstract Background Proton pump inhibitors (PPIs) are commonly prescribed for the
treatment of acid-related disorders. In the context of coronary artery disease (CAD), PPIs are …
treatment of acid-related disorders. In the context of coronary artery disease (CAD), PPIs are …
Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?
AA Manolis, TA Manolis, H Melita, N Katsiki… - European Journal of …, 2020 - Elsevier
Proton pump inhibitors (PPIs) are among the most widely prescribed agents, either for
treatment or prophylaxis of gastrointestinal (GI) disease, that are often administered for …
treatment or prophylaxis of gastrointestinal (GI) disease, that are often administered for …
Management of bleeding and procedures in patients on antiplatelet therapy
D Swan, N Loughran, M Makris, J Thachil - Blood Reviews, 2020 - Elsevier
Antiplatelet medications have long been the mainstay for secondary prevention in
cardiovascular disorders. More recently, with the advent of coronary stents, there has been …
cardiovascular disorders. More recently, with the advent of coronary stents, there has been …
Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with …
RJ Jia, XP Wang, ZH Zhang, HH Cui… - Clinical and Applied …, 2022 - journals.sagepub.com
To investigate the therapeutic effect of rabeprazole and rebamipide on patient age over 60
with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following …
with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following …
[HTML][HTML] Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: a subanalysis of the ANAFIE registry
Y Mizokami, T Yamamoto, H Atarashi, T Yamashita… - PLoS …, 2020 - journals.plos.org
The real-world status of proton pump inhibitor (PPI) use in patients with atrial fibrillation (AF)
receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly …
receiving antithrombotic treatment is largely unknown. The All Nippon AF In the Elderly …